Elanco Animal Health (NYSE:ELAN) Price Target Raised to $20.00 at Barclays

Elanco Animal Health (NYSE:ELAN) had its price target raised by analysts at Barclays from $19.00 to $20.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 41.24% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health has an average rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Price Performance

Shares of NYSE ELAN traded down $0.34 during midday trading on Friday, reaching $14.16. The company’s stock had a trading volume of 2,461,932 shares, compared to its average volume of 4,774,452. The company has a market cap of $7.00 billion, a P/E ratio of -5.56, a P/E/G ratio of 1.31 and a beta of 1.41. Elanco Animal Health has a fifty-two week low of $10.19 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The business’s 50 day moving average price is $13.95 and its two-hundred day moving average price is $14.71.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s revenue was down 3.6% on a year-over-year basis. During the same quarter last year, the business earned $0.18 earnings per share. On average, analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Activity

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the acquisition, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Michael J. Harrington bought 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the transaction, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the purchase, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The trade was a 200.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Elanco Animal Health in the first quarter valued at $1,226,000. Janney Montgomery Scott LLC boosted its holdings in Elanco Animal Health by 4.3% in the first quarter. Janney Montgomery Scott LLC now owns 63,978 shares of the company’s stock worth $1,042,000 after acquiring an additional 2,659 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Elanco Animal Health in the first quarter valued at approximately $535,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Elanco Animal Health during the first quarter valued at approximately $197,000. Finally, Atomi Financial Group Inc. acquired a new position in shares of Elanco Animal Health during the first quarter worth approximately $180,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.